Shattuck Labs Soars on $103M Private Placement and SL-325 IND Filing
By ATTN Desk · Editorial oversight: Sean Han
Introduction
SHATTUCK LABS INC (NASDAQ: STTK; 선택 랩) is a biotechnology company focused on protein engineering to develop therapeutics targeting tumor necrosis factor (TNF) receptors. The company’s lead program, SL-325, is a monoclonal antibody antagonist of Death Receptor 3 (DR3) designed to achieve blockade of the TL1A/DR3 pathway relevant to inflammatory bowel disease (IBD) and other autoimmune conditions.
| Metric | Value |
|---|---|
| Share Price (2025-09-02 close) | $1.3072 (+29.43 %) |
| Volume | 8,406,284 |
| Exchange | NASDAQ |
| Market Capitalization (8/25) | $47.6 million |
| 52-Week Range | $0.692 – $3.950 |
| Total Cash (Q2 2025) | $50.5 million |
| Employees | 51 – 200 |
Corporate Structure
Founded in 2016, Shattuck Labs is based in Austin, Texas, and Durham, North Carolina. The management team includes Taylor H. Schreiber, M.D., Ph.D., co-founder and Chief Executive Officer, who oversees the ARC protein engineering platform. The board comprises George Golumbeski, Ph.D., former Executive Vice President of Business Development at Celgene; Helen M. Boudreau, former COO of the Bill & Melinda Gates Medical Research Institute; and Neil Gibson, Ph.D., Chief Scientific Officer at COI Pharmaceuticals, among others.
Biotechnology by Sangharsh Lohakare
Recent Developments and News
In August 2025, Shattuck Labs reported its second-quarter financial results and noted two key milestones: an oversubscribed private placement of up to $103 million and the submission of an Investigational New Drug (IND) application for SL-325, which is set to begin a Phase 1 trial in healthy volunteers. The proceeds from the private placement are designated to support multiple Phase 2 studies in IBD and an additional autoimmune condition.
In August 2025, the company’s leadership participated in several investor conferences, including the 24th Annual Needham Virtual Healthcare Conference, the European Crohn’s and Colitis Organization (ECCO) meeting, and the 36th Annual Piper Sandler Healthcare Conference.
Institutional investors have reported significant stakes:
- On August 26, 2025, Redmile Group, LLC filed a Schedule 13D/A indicating a 9.9% ownership stake, including shares underlying warrants.
- On September 2, 2025, OrbiMed Advisors LLC and affiliated entities disclosed a combined beneficial ownership of approximately 18% via Schedule 13D filings.
Financial and Strategic Analysis
Shattuck Labs reported a cash balance of $50.5 million at the end of Q2 2025, bolstered by the $103 million from the private placement. As of August 25, 2025, the company's market capitalization was $47.6 million, reflecting increased trading activity after the IND submission announcement. The balance sheet shows limited debt (total debt/equity ratio around 5%) and a net loss of $61.5 million over the trailing twelve months, which is consistent with a pre-revenue research and development investment profile.
Strategically, SL-325 is positioned as a first-in-class DR3 antagonist. Preclinical data suggest it may demonstrate greater inhibition of the TL1A/DR3 pathway compared to existing therapies targeting TL1A. The support from OrbiMed and Redmile reflects investor engagement with Shattuck’s development strategy.
Market Position and Industry Context
Shattuck Labs functions within the biologics sector focused on autoimmune and inflammatory diseases, where established treatments include TNF inhibitors like infliximab and adalimumab. The TL1A/DR3 axis is considered a validated but under-utilized target. SL-325 combines high-affinity epitope specificity with Fc-silencing, which may enhance the depth and durability of therapeutic responses. If the Phase 1 safety and dosing data are positive, Shattuck plans to advance to Phase 2 trials, targeting a market projected to surpass $30 billion in annual IBD therapeutic sales by 2030.
tl;dr
As of September 2, 2025, SHATTUCK LABS INC (NASDAQ: STTK) closed at $1.3072, reflecting a 29.43% increase on a volume of 8.4 million shares. In August 2025, the company secured a private placement of up to $103 million and submitted an IND for SL-325 to initiate a Phase 1 trial in healthy volunteers. Notable institutional investors, Redmile Group and OrbiMed affiliates, now hold approximately 10% each. Cash reserves amount to $50.5 million, positioning Shattuck to commence multiple Phase 2 studies in IBD and another autoimmune indication. Upcoming highlights include Phase 1 data releases and the initiation of Phase 2 trials.